+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Haploidentical bone marrow transplantation in leukemia and genetic diseases



Haploidentical bone marrow transplantation in leukemia and genetic diseases



Haematologica 85(11 Suppl.): 37-40



From 1986 to June 2000, sixty children suffering from acute and chronic leukemia (n = 42, 33 of which in resistant relapse), genetic diseases (n = 11), aplastic anemia (n = 2, one of which with platelet refractoriness and bleeding), myelodysplasia (n = 5) received an haploidentical bone marrow, mismatched for 2-3 HLA loci. The donor's marrow was treated in vitro with vincristine and methylprednisolone to obtain a functional T depletion (MLC and CTL inhibition, functional blockade of Th1 and Th2). The prevalence of infectious complications and GVHD was similar to that recorded in matched unrelated donor (MUD) transplants. In situations of high risk of rejection (chronic leukemia, genetic diseases) we infused immediately one half of the harvest and then frozen aliquots from the second week. Of the 25 ALL and 8 AML in resistant relapse, 3 survived, disease-free at 14, 8 and 1 years respectively. Of the 3 ALL, transplanted during remission, 1 is surviving at 18 months. Of the 6 CML, 1 had fractionated bone marrow and is surviving at 3 years, and 5 had standard single dose infusion and died of progression of their disease after rejection of the graft (4) or blast crisis after complete engraftment (1). The 2 patients with aplastic anemia, those with myelodysplasia, and 6 of the 10 with genetic disorders died of transplant-related complications or disease progression. 4 patients with osteopetrosis (n = 2), MLD (n = 1), Wiskott Aldrich dis. (n = 1) survive at 8, 2, 5 and 1.5 years respectively. In patients transplanted with fractionated marrow GVHD > 2nd grade occurred in 15%. Only one patient rejected the graft. Compared with MUD transplantation, mismatched BMT whenever performed in patients in good conditions provides similar outcome and widens the donor availability.

(PDF emailed within 1 workday: $29.90)

Accession: 046211949

Download citation: RISBibTeXText

PMID: 11268322


Related references

Haploidentical bone marrow transplantation from mother to child with advanced leukemia. Bone Marrow Transplantation 16(4): 529-535, 1995

Bone marrow transplantation from haploidentical mother in children with acute leukemia in relapse. Bone Marrow Transplantation 5(SUPPL 2): 75, 1990

Hvg and gvhd prediction by analysis of ctl precursors before haploidentical bone marrow transplantation for acute leukemia. Experimental Hematology 18(6): 687, 1990

Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biology of Blood and Marrow Transplantation 15(2): 257-265, 2009

Clinical study on hematopoietic reconstitution in patients with leukemia by haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 11(4): 416-419, 2003

Acute leukemia relapse of donor origin in two cases after haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14(2): 400-402, 2006

Clinical investigation on treatment of children leukemia with non-T-cell depleted haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(1): 101-105, 2008

Treatment of leukemia with immunized donor cell infusion after nonmyeloablative haploidentical bone marrow transplantation. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21(3): 711-715, 2014

Attempted haploidentical bone marrow transplantation bmt in 3 patients with lysosomal storage diseases lsds. Experimental Hematology 18(6): 702, 1990

HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biology of Blood and Marrow Transplantation 20(3): 314-318, 2014

Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology 38(1): E39-E41, 2016

Molecular characteristics of T-cell receptor of clonal expansion of T lymphocytes in leukemia patients after haploidentical bone marrow transplantation. Ai Zheng 26(3): 236-240, 2007

Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors. Bone Marrow Transplantation 18(4): 747-753, 1996

Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents. International Journal of Hematology 80(1): 78-82, 2004

CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia. Zhonghua Er Ke Za Zhi 42(4): 294-298, 2004